BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hu C, Dignam JJ. Biomarker-Driven Oncology Clinical Trials: Key Design Elements, Types, Features, and Practical Considerations. JCO Precis Oncol 2019;3:PO. [PMID: 32923854 DOI: 10.1200/PO.19.00086] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
Number Citing Articles
1 Park Y. Personalized Risk-Based Screening Design for Comparative Two-Arm Group Sequential Clinical Trials. JPM 2022;12:448. [DOI: 10.3390/jpm12030448] [Reference Citation Analysis]
2 Rocca A, Kholodenko BN. Can Systems Biology Advance Clinical Precision Oncology? Cancers (Basel) 2021;13:6312. [PMID: 34944932 DOI: 10.3390/cancers13246312] [Reference Citation Analysis]
3 Mowday AM, Copp JN, Syddall SP, Dubois LJ, Wang J, Lieuwes NG, Biemans R, Ashoorzadeh A, Abbattista MR, Williams EM, Guise CP, Lambin P, Ackerley DF, Smaill JB, Theys J, Patterson AV. E. coli nitroreductase NfsA is a reporter gene for non-invasive PET imaging in cancer gene therapy applications. Theranostics 2020;10:10548-62. [PMID: 32929365 DOI: 10.7150/thno.46826] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
4 Tan AC, Bagley SJ, Wen PY, Lim M, Platten M, Colman H, Ashley DM, Wick W, Chang SM, Galanis E, Mansouri A, Khagi S, Mehta MP, Heimberger AB, Puduvalli VK, Reardon DA, Sahebjam S, Simes J, Antonia SJ, Berry D, Khasraw M. Systematic review of combinations of targeted or immunotherapy in advanced solid tumors. J Immunother Cancer 2021;9:e002459. [PMID: 34215688 DOI: 10.1136/jitc-2021-002459] [Reference Citation Analysis]
5 Wang T, Denman D, Bacot SM, Feldman GM. Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy. Biomedicines 2022;10:1181. [DOI: 10.3390/biomedicines10051181] [Reference Citation Analysis]